Efficacy of smallpox approved tecovirimat (Tpoxx) drug against Monkeypox: current update and futuristic prospects

Review Immunology

Antivirals With Activity Against Monkeypox: A Clinically Oriented Review

Emily A. Siegrist et al.

Summary: This review provides an overview of the basic pharmacology, animal data, and human data for three antivirals (cidofovir, brincidofovir, and tecovirimat) with activity against monkeypox virus. These antiviral agents have shown varying degrees of efficacy against monkeypox and other orthopoxviruses, highlighting their potential importance in the research and treatment of monkeypox virus infection.

CLINICAL INFECTIOUS DISEASES (2023)

Add to Collection

Article Infectious Diseases

Clinical features and management of human monkeypox: a retrospective observational study in the UK

Hugh Adler et al.

Summary: This study retrospectively observed the clinical course of monkeypox in seven patients in the UK from 2018 to 2021. The study found that prolonged PCR positivity led to isolation of five patients for more than 3 weeks. Three patients treated with brincidofovir developed elevated liver enzymes, leading to termination of the therapy. One patient treated with tecovirimat experienced no adverse effects and had a shorter duration of viral shedding and illness compared to the other six patients.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Letter Infectious Diseases

Targeting F13 from monkeypox virus and variola virus by tecovirimat: Molecular simulation analysis

Daoqun Li et al.

JOURNAL OF INFECTION (2022)

Add to Collection

Article Immunology

Tecovirimat for the Treatment of Human Monkeypox: An Initial Series From Massachusetts, United States

Wilfredo R. Matias et al.

Summary: Three patients with monkeypox were treated with tecovirimat, a pan-Orthopoxvirus inhibitor, and the results showed the potential efficacy of this drug in treating monkeypox.

OPEN FORUM INFECTIOUS DISEASES (2022)

Add to Collection

Letter Medicine, General & Internal

Compassionate Use of Tecovirimat for the Treatment of Monkeypox Infection

Angel N. Desai et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Add to Collection

Article Medicine, General & Internal

Human monkeypox virus infection in an immunocompromised man: trial with tecovirimat

Loren E Hernandez et al.

LANCET (2022)

Add to Collection

Editorial Material Multidisciplinary Sciences

Call for a unified approach to Monkeypox infection in pregnancy: Lessons from the COVID-19 pandemic Comment

Asma Khalil et al.

Summary: In the current monkeypox outbreak, vaccination and treatment of pregnant women are recommended only if the benefits outweigh risks, but the limited data available hinders evidence-based recommendations. It is crucial to establish a unified consensus approach to promptly gather robust data. Two years into the COVID-19 pandemic, monkeypox has emerged as an additional challenge to the well-being of both mother and fetus.

NATURE COMMUNICATIONS (2022)

Add to Collection

Letter Surgery

Clinical management, antiviral drugs and immunotherapeutics for treating monkeypox. An update on current knowledge and futuristic prospects

Sandip Chakraborty et al.

INTERNATIONAL JOURNAL OF SURGERY (2022)

Add to Collection

Review Infectious Diseases

An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications

Andrew T. Russo et al.

Summary: The approval of tecovirimat for smallpox treatment marks a significant milestone in biosecurity preparedness. Incorporating tecovirimat into the CDC smallpox response plan and further developing it for potential use against other orthopoxvirus diseases like monkeypox demonstrates its broad efficacy.

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2021)

Add to Collection

Article Medicine, Research & Experimental

Estimation of Absolute Bioavailability of the Chemical Substance of the Anti-Smallpox Preparation NIOCH-14 in Mice

O. Yu Mazurkov et al.

BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE (2020)

Add to Collection

Article Virology

An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge

G Yang et al.

JOURNAL OF VIROLOGY (2005)

Add to Collection

Efficacy of smallpox approved tecovirimat (Tpoxx) drug against Monkeypox: current update and futuristic prospects

Related references

Export Citation

Share Paper